StockData

Ultragenyx Pharmaceutical vs Travere Therapeutics

RARE and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RARE and TVTX compare

Travere Therapeutics is the larger company, worth 3.0 times as much as Ultragenyx Pharmaceutical ($4.7B against $1.6B).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 17.5% for Ultragenyx Pharmaceutical).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −81.7% at Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRARETVTX
Size and price
Market cap$1.6B$4.7B
Share price$15.90$49.70
Change, 1 year−51.7%46.7%
Change, 5 years−79.2%71.2%
Beta (5Y)2.201.95
Employees1,371497
StockData Score
Total score9 (better)6
Valuation score1 (better)0
Growth score23 (better)
Performance score12 (better)
Health score5 (better)1
Dividend score00
Valuation
P/S2.2× (better)7.9×
P/B–191×
EV/EBITDA–192×
FCF yield−31.2%–
Fair value–$6.04
Margin of safety–−723%
Growth
Revenue growth (TTM)17.5%77.1% (better)
Revenue growth, 5Y average19.9% (better)19.9%
Profitability
Gross margin–98.6%
Operating margin−73.6%−6.8% (better)
Net margin−81.7%−7.4% (better)
FCF margin−68.2%–
Return on equity–−152%
Financial health
Interest coverage–−4.3×
Current ratio1.734.05 (better)
Altman Z-score−5.292.19 (better)
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions108%112%
Held by insiders4.0%1.6%
Insider net buying, 12 months−$3.8M (better)−$110M
Short interest, % of float25.0%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.